Samsung Bioepis Company Profile: Valuation, Investors, Acquisition | PitchBook
FDA Accepts Ranibizumab BLA From Samsung Bioepis and Biogen
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
Samsung Biologics - Wikipedia
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
Samsung Bioepis' Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the U.S. Food and Drug Administration | Business Wire
Samsung Bioepis (@SamsungBioepis) / X
Samsung Bioepis Obtains Two ISO Certifications for Environmental Management System and Energy Management System - ESG News
Samsung Biologics completes full acquisition of Samsung Bioepis
Samsung Biologics: All Eyes on Plant 5 and Samsung Bioepis - Businesskorea
PharmaBoardroom - Samsung Bioepis
Samsung Bioepis races rivals as EMA accepts Herceptin biosim app | Fierce Biotech
Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Yonhap News Agency
Samsung Bioepis enters US market for biosimilars of Humira - KED Global
Samsung Bioepis Initiates Phase 3 Trial for Denosumab Biosimilar
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates | Business Wire
Samsung Bioepis DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada - KED Global
Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars | Ophthalmology Innovation Source
Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets | Be Korea-savvy
